MicroRNA Regulation in Kidney Interstitial Fibrosis

Hirofumi Sakuma1, Satoshi Kawaguchi1,2, Yuya Kobayashi1

  • 1Division of Cardiology and Nephrology, Department of Internal Medicine, Asahikawa Medical University, Asahikawa 078-8510, Japan.

Epigenomes
|March 27, 2026
PubMed

Insights

MicroRNAs (miRNAs) are key regulators in chronic kidney disease (CKD) progression. This review explores how miRNAs impact fibrosis and their potential as CKD biomarkers and therapeutic targets.

Area of Science:

  • Molecular Biology
  • Nephrology
  • Genetics

Background:

  • MicroRNAs (miRNAs) are crucial for gene regulation and cellular balance.
  • miRNA dysregulation contributes significantly to tissue injury and chronic kidney disease (CKD) progression.
  • Interstitial fibrosis, a hallmark of CKD, involves complex cellular changes.

Purpose of the Study:

  • To review miRNA-mediated regulation in CKD.
  • To emphasize miRNA roles in fibrotic pathways and cell lineages.
  • To discuss miRNA potential as CKD biomarkers and therapeutic targets.

Main Methods:

  • Literature review focusing on miRNA functions in CKD.
  • Analysis of miRNA involvement in fibroblast activation and cell phenotypic transitions.
  • Examination of disease-specific miRNA dysregulation in various CKD etiologies.

Main Results:

  • miRNAs are identified as critical regulators of interstitial fibrosis in CKD.
  • Dysregulated miRNAs are detected across different CKD causes like diabetic kidney disease and glomerulonephritis.
  • Specific miRNAs influence fibroblast activation and tubular epithelial cell transitions.

Conclusions:

  • miRNAs play multifaceted roles in CKD pathogenesis, particularly in fibrosis.
  • miRNAs represent promising biomarkers for CKD diagnosis and prognosis.
  • Targeting miRNAs offers a potential therapeutic strategy for managing CKD.